T. Mills Kenneth's Insider Trades & SAST Disclosures
T. Mills Kenneth's most recent trade in Regenxbio Inc was a trade of 36,316 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Aug. 8, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern T. Mills Kenneth.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 36,316 | 0 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 08 Aug 2024 | 36,316 | 444,351 (1%) | 0% | 0.9 | 30,869 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2024 | 15,369 | 51,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Sale of securities on an exchange or to another person at price $ 13.96 per share. | 24 Jul 2024 | 15,369 | 408,035 (1%) | 0% | 14.0 | 214,501 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 24 Jul 2024 | 15,369 | 423,404 (1%) | 0% | 3.8 | 57,787 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 24 Jul 2024 | 12,221 | 420,256 (1%) | 0% | 3.8 | 45,951 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2024 | 12,221 | 66,723 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Sale of securities on an exchange or to another person at price $ 13.78 per share. | 24 Jul 2024 | 12,221 | 408,035 (1%) | 0% | 13.8 | 168,433 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 2,210 | 78,944 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Sale of securities on an exchange or to another person at price $ 13.77 per share. | 16 Jul 2024 | 2,210 | 408,035 (1%) | 0% | 13.8 | 30,440 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 16 Jul 2024 | 2,210 | 410,245 (1%) | 0% | 3.8 | 8,310 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Sale of securities on an exchange or to another person at price $ 13.76 per share. | 16 Jul 2024 | 200 | 408,035 (1%) | 0% | 13.8 | 2,752 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 200 | 81,154 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 16 Jul 2024 | 200 | 408,235 (1%) | 0% | 3.8 | 752 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 15,000 | 81,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.81 per share. | 14 May 2024 | 15,000 | 408,035 (1%) | 0% | 15.8 | 237,222 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 14 May 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 15 Apr 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 15,000 | 96,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.19 per share. | 15 Apr 2024 | 15,000 | 408,035 (1%) | 0% | 18.2 | 272,871 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 15,000 | 111,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 21.86 per share. | 14 Mar 2024 | 15,000 | 408,035 (1%) | 0% | 21.9 | 327,942 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 14 Mar 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 14 Feb 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 15,000 | 126,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.88 per share. | 14 Feb 2024 | 10,348 | 408,035 (1%) | 0% | 16.9 | 174,723 | Common Stock |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.47 per share. | 14 Feb 2024 | 4,652 | 418,383 (1%) | 0% | 16.5 | 76,626 | Common Stock |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 45,000 | 141,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.18 per share. | 16 Jan 2024 | 45,000 | 408,035 (1%) | 0% | 15.2 | 682,992 | Common Stock |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 16 Jan 2024 | 45,000 | 453,035 (1%) | 0% | 3.8 | 169,200 | Common Stock |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 305,250 | 305,250 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Mills T. Kenneth | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 64,103 | 408,035 (1%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.95 per share. | 02 Jan 2024 | 11,357 | 343,932 (0%) | 0% | 17.9 | 203,858 | Common Stock |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.68 per share. | 19 Dec 2023 | 45,000 | 355,289 (0%) | 0% | 19.7 | 885,825 | Common Stock |
| Regenxbio Inc | T. Mills Kenneth | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 43,500 | 186,354 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 19 Dec 2023 | 43,500 | 398,789 (1%) | 0% | 3.8 | 163,560 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 1,500 | 36,316 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 19 Dec 2023 | 1,500 | 400,289 (1%) | 0% | 0.9 | 1,275 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 264,932 | 264,932 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 54,753 | 355,289 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.68 per share. | 03 Jan 2023 | 9,308 | 300,536 (0%) | 0% | 22.7 | 211,105 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 170,188 | 170,188 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 35,796 | 309,844 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.70 per share. | 01 Jan 2022 | 3,636 | 274,048 (0%) | 0% | 32.7 | 118,897 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2021 | 3,300 | 277,684 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 08 Nov 2021 | 1,500 | 280,984 (0%) | 0% | 40 | 60,000 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2021 | 1,500 | 229,854 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 08 Nov 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.19 per share. | 27 Sep 2021 | 1,500 | 280,984 (0%) | 0% | 42.2 | 63,285 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2021 | 1,500 | 231,354 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 27 Sep 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.11 per share. | 13 Sep 2021 | 35,000 | 280,984 (0%) | 0% | 45.1 | 1,578,850 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 33,146 | 232,854 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 13 Sep 2021 | 33,146 | 314,130 (0%) | 0% | 3.8 | 124,629 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 3,000 | 266,000 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 13 Sep 2021 | 3,000 | 280,984 (0%) | 0% | 40.0 | 120,060 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 13 Sep 2021 | 3,000 | 283,984 (0%) | 0% | 3.8 | 11,280 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 1,854 | 37,816 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 13 Sep 2021 | 1,854 | 315,984 (0%) | 0% | 0.9 | 1,576 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 24 Jun 2021 | 4,500 | 280,984 (0%) | 0% | 40.0 | 180,090 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 24 Jun 2021 | 4,500 | 285,484 (0%) | 0% | 3.8 | 16,920 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 4,500 | 270,500 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 24 Jun 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2021 | 1,500 | 269,000 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.25 per share. | 24 Jun 2021 | 1,500 | 280,984 (0%) | 0% | 40.3 | 60,375 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.77 per share. | 25 Feb 2021 | 1,500 | 280,984 (0%) | 0% | 40.8 | 61,155 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 1,500 | 39,670 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 25 Feb 2021 | 1,500 | 282,484 (0%) | 0% | 0.9 | 1,275 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 25 Jan 2021 | 6,500 | 287,484 (0%) | 0% | 0.9 | 5,525 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 6,500 | 41,170 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.99 per share. | 25 Jan 2021 | 5,211 | 280,984 (0%) | 0% | 45.0 | 234,443 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 44.05 per share. | 25 Jan 2021 | 974 | 286,195 (0%) | 0% | 44.1 | 42,905 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 42.64 per share. | 25 Jan 2021 | 315 | 287,169 (0%) | 0% | 42.6 | 13,432 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 07 Jan 2021 | 1,500 | 283,484 (0%) | 0% | 0.9 | 1,275 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2021 | 1,500 | 47,670 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 50.01 per share. | 07 Jan 2021 | 1,500 | 281,984 (0%) | 0% | 50.0 | 75,015 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 185,167 | 185,167 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 40,984 | 281,984 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2020 | 6,500 | 49,170 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 28 Dec 2020 | 6,500 | 247,500 (0%) | 0% | 0.9 | 5,525 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 48.47 per share. | 28 Dec 2020 | 4,647 | 242,853 (0%) | 0% | 48.5 | 225,240 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 49.16 per share. | 28 Dec 2020 | 1,853 | 241,000 (0%) | 0% | 49.2 | 91,093 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 23 Dec 2020 | 4,500 | 241,000 (0%) | 0% | 50 | 225,000 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2020 | 4,500 | 55,670 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 23 Dec 2020 | 4,500 | 245,500 (0%) | 0% | 0.9 | 3,825 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 16 Dec 2020 | 15,000 | 241,000 (0%) | 0% | 45 | 675,000 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2020 | 15,000 | 60,170 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 16 Dec 2020 | 15,000 | 256,000 (0%) | 0% | 0.9 | 12,750 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Dec 2020 | 4,500 | 241,000 (0%) | 0% | 40 | 180,000 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2020 | 4,500 | 75,170 | - | - | Employee Stock Option (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.85 per share. | 10 Dec 2020 | 4,500 | 245,500 (0%) | 0% | 0.9 | 3,825 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges